Physician profile
James E Tooley
NPI 1467531756
$2,416.13
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $556 · 2021: $661 · 2022: $737.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $570.97 | 2019-2022 | |
| Abbvie INC. | $407.59 | 2019-2022 | |
| Pfizer INC. | $150.38 | 2019-2021 | |
| Allergan, INC. | $139.17 | 2020 | |
| Glaxosmithkline, LLC. | $128.29 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.64 | 2020-2022 | |
| Abbott Laboratories | $86.06 | 2021-2022 | |
| Esperion Therapeutics, INC. | $66.31 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.09 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $64.05 | 2021 | |
| Almatica Pharma LLC | $60.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.55 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $54.08 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $42.56 | 2021-2022 | |
| Amarin Pharma, INC. | $39.18 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $38.05 | 2019-2022 | |
| Genentech USA, INC. | $36.76 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.45 | 2021 | |
| Horizon Therapeutics Plc | $34.45 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.14 | 2022 | |
| Ethicon US, LLC | $30.84 | 2021 | |
| Jazz Pharmaceuticals INC. | $30.04 | 2019 | |
| Merck Sharp & Dohme LLC | $29.88 | 2020 | |
| Lilly USA, LLC | $27.78 | 2020-2022 | |
| Nabriva Therapeutics, Plc | $25.86 | 2020 | |
| Ucb, INC. | $18.33 | 2019 | |
| Dexcom, INC. | $14.21 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.